Objective: High-dose vitamin C therapy might mediate beneficial clinical effects by counteracting reactive oxygen species. However, concerns are raised whether this approach might provoke diametrical (ie pro-oxidative) effects. The objective was to determine ascorbyl free radical (AFR) concentrations and potential variables of pro-oxidative damage. Design: Crossover study; six healthy males received daily infusions of 750 or 7500 mg vitamin C for six consecutive days. Fasting concentrations of vitamin C and AFR were determined daily. On day 1, concentrations of vitamin C and AFR were measured at 0.25, 0.5, 1, 2, 4 and 8 h post infusion. Plasma concentrations of thiobarbituric acid-reactive substances (TBARS), tocopherol and urine concentrations of 8-oxoguanosine were determined on days 1 and 6. Results: Kinetic studies on day 1 showed that concentrations of vitamin C and AFR displayed parallel dose-and time-dependent kinetics and elimination was highly efficient. Vitamin C and AFR fasting concentrations on days 2-6 were slightly above the baseline, suggesting new, stable steady states. TBARS decreased in both groups, whereas tocopherol and 8-oxoguanosine concentrations remained unchanged. Conclusion: Kinetics of AFR largely depend on plasma vitamin C concentrations and AFR is eliminated efficiently. Our data do not support induction of pro-oxidative effects in healthy volunteers given intravenous high-dose vitamin C. Sponsorship:
Introduction
There is increasing evidence that high-dose vitamin C therapy might mediate beneficial effects in a variety of clinical situations, in which overproduction of reactive oxygen species (ROS) is a crucial pathophysiological factor. Recently, it has been demonstrated that vitamin C reverses endothelial dysfunction by its powerful anti-oxidative action. This is seen in severe burns, renal allograft recipients and coronary artery disease (Tanaka et al, 2000; Ellis et al, 2001; Heitzer et al, 2001; Williams et al, 2001) . For example, the application of high-dose vitamin C (up to 110 g during the first 24 h) after a burn injury significantly reduced resuscitation fluid requirements and wound edema (Tanaka et al, 2000) . Apart from the unequivocally proven antioxidative effects of vitamin C, pro-oxidative mechanisms mediated by vitamin C are also discussed (Podmore et al, 1998; Cai et al, 2001; Guidarelli et al, 2001) .
The removal of an electron (eg by ROS, tocopherol radical) from ascorbic acid results in the generation of ascorbic free radical (AFR). By removing another electron (eg ROS, AFR) dehydro ascorbic acid (DHAA) is formed. DHAA is either reduced to ascorbate or irreversibly hydrolyzed to di-keto gulonic acid, a precursor of oxaluric acid (Pence & Mennear, 1979; Bianchi & Rose, 1986; Rose et al, 1992) . Alternatively, transmembrane AFR reductases have been described in erythrocytes and liver that convert AFR to ascorbate in a NADH-dependent manner (Goldenberg et al, 1983; Villalba et al, 1993; May et al, 2000 May et al, , 2001 .
AFR is generally considered a relatively stable radical (Van Duijn et al, 2000) . However, it might account for assumed pro-oxidative damages by vitamin C. This hypothesis has not been clearly proven in vivo, yet. In a recently published study by Lee, it was demonstrated that vitamin C induced lipid hydroperoxide decomposition to DNA-reactive derivates in a cell-free system, though the concentration of the crucial intermediate AFR was not determined (Lee et al, 2001 ). Moreover, DNA-damaging mechanisms, such as radiation or incubation with peroxynitrite, are enhanced by vitamin C, particularly in the presence of free transition metals (Cai et al, 2001; Guidarelli et al, 2001) . However, the potentially toxic natures of these factors might be limited due to effective detoxification systems in vivo.
The effect of oral intake of 500 mg vitamin C for 6-8 weeks on oxidative DNA damage products 8-oxoadenosine and 8-oxoguanosine yielded controversial results. Whereas one group found that 8-oxoadenosine was increased in contrast to a decrease of 8-oxoguanosine in lymphocytes, the other group was not able to demonstrate a decrease of 8-oxoguanosine in the urine (Priemé et al, 1997; Podmore et al, 1998) .
Our own group studied the effect of high-dose vitamin C (1 g/day for 1 week) in smokers as compared to non-smokers. The supplementation resulted in an increase of both vitamin C and AFR in the plasma with a concomitant decrease of micronuclei in lymphocytes, an established marker for DNA damaging (Schneider et al, 2001) . Based on these results, we had no evidence for DNA damage mediated by vitamin C and AFR. Taken together, it is not clear whether anti-or prooxidative effects predominate during high-dose vitamin C therapy.
As it can be foreseen that high-dose vitamin C therapy might be indicated in a variety of clinical situations that share an increased formation of ROS (see above), it is necessary to exclude that high-dose vitamin C therapy induces pro-oxidative effects in humans. Therefore, the aim of our study was to determine the effect of high-dose intravenous vitamin C therapy on plasma concentrations of vitamin C/AFR and the potential variables of pro-oxidative damage.
Methods

Study population
The study population consisted of six healthy, male, nonsmoking volunteers. The age was between 24 and 33 y. The body mass index was not exceeding 25 kg/m 2 . Exclusion criteria were chronic diseases, substance abuse, iron storage diseases (or history of a close family member) and a history of urolithiasis. Vitamin supplements had to be stopped 4 weeks before inclusion and were not allowed during the entire study period. To exclude renal insufficiency, serum creatinine and urine analysis were performed prior to inclusion in the study.
The study was approved by the regional ethics committee (Landesärztekammer Baden-Württemberg; PSC 129/00).
Study design
This open, prospective study with a crossover design was performed at Katharinenhospital Stuttgart. The study subjects were recruited 4 weeks prior to inclusion. The screening exam included a thorough history and physical exam. At the time point of inclusion (10 days prior to the first vitamin C infusion) and on the day before the second study period (see below), a baseline complete laboratory analysis (fasting state; hemoglobin, leukocytes, thrombocytes, sodium, potassium, calcium, chloride, glucose, creatinine, urea, bilirubine, ALT, AST, gGT, alkaline phosphatase, protein including electrophoresis, prothrombin time; urine analysis with erythrocytes, protein and glucose; drug screening with alcohol, opiate, benzodiazepame) was performed in addition to the variables mentioned below. The values obtained at these time points refer to baseline concentrations. The ECG was normal in all subjects.
At the time of inclusion, the subjects received intensive nutritional counselling to ensure that daily intake of vitamin C did not exceed 100 mg. During the study periods, standardized meals, containing approximately 80 mg vitamin C/d, were provided. Tea and mineral water were the only beverages allowed.
Subjects were then randomized to receive a daily intravenous dose of either 7500 or 750 mg of ascorbic acid on days 1-6 (subsequently also called repetitive vitamin C infusions). The 750 mg dose was infused over a period of 10 min and the 7500 mg dose over 30 min, respectively. As we chose a crossover design, during the second study period, the subjects that received 7500 mg daily during the initial study period before received 750 mg daily and vice versa. The second study period also lasted 6 days and was separated by a washout period of 4 weeks.
Prior to intravenous infusion of vitamin C on days 1-6, fasting morning blood samples were drawn and immediately put on ice. After centrifugation at 500 Â g for 5 min at 41C, plasma supernatants were aliquoted. For vitamin C and TBARS analysis (see below), metaphosphoric acid or BHT (2,6-di-tert-butyl-4-methylphenol) were added, respectively. Additional blood samples were drawn on day 1 for kinetic studies and on days 2-6 at 4 and 8 h post infusion, as outlined in Results section.
Urine was collected in dark containers for 24 h at room temperature.
Hematocrit was monitored daily and a complete laboratory analysis (see above) was performed on days 0 and 6. In addition, all the volunteers received an ECG on days 0 and 6.
Determination of ascorbic acid
Plasma concentrations of ascorbic acid were determined using a modified reversed phase HPLC system equipped with a PED 300 pulsed electrochemical detector (Biometra, Germany) and a C 18 -column Grom-Sil 120 Amino-2 PA (particle size 5 mmol/l, 250 Â 4 mm, Grom, Germany), which operates at 0.5 ml/min. (Bates, 1992) . In brief, metaphosphoric acid-treated plasma samples were thawed and the upper phases were vortexed with methanol/H 2 O (2/8). Then, all proteins were precipitated by centrifugation (16 000 Â g, 221C, 5 min) and 20 ml of the upper phase was injected into the HPLC system. As the mobile phase, 10% methanol in double-distilled water containing 10 mmol/l hexadecyltrimethyl-ammonium bromide, 10 mmol/l NaCl, 0.6 mmol/l Na 2 EDTA and 140 mmol/l acetic acid was used. The pH was adjusted to 4.0 with 4 mol/l NaOH. All determinations, as well as all the following, were done in duplicates.
Determination of a-tocopherol
Plasma concentrations of a-tocopherol were determined using a modification of an HPLC method previously described (Biesalski et al, 1986) . In brief, 200 ml human plasma samples were extracted twice with 500 ml hexane after precipitation of the proteins with 200 ml ethanol. The hexane phase was separated, dried under a continuous stream of nitrogen, and subsequently redissolved in 200 ml hexane. atocopherol was separated on a 250 Â 4 mm Merck LiChrosphere CN column using hexane as the eluent. The detection was performed by UV (293 nmol/l, UV/VIS Detector, Kontron, Germany).
Determination of ascorbic acid radical by electron paramagnetic resonance (EPR)
Freshly obtained blood samples were immediately put on ice, then centrifuged at 500 Â g at 41C for 5 min. Plasma was directly transferred to liquid nitrogen and samples were stored at À801C until analysis. EPR spectra were recorded at 293 K using a Bruker ESP 300E spectrometer, equipped with a Bruker TE 102 (ER 4104ST) cavity, operating at 9.6 GHz with a 100 kHz modulation frequency. A microwave power of 6.3 mW was typically employed. For EPR analysis, plasma samples were thawed at room temperature in the dark and 60 ml was transferred within 10 min to a flat cell. No specific trapper was added. The total radical concentration was determined by measuring the peak-to-peak amplitude. The mean values for each study subject were obtained by multiple analysis of duplicate plasma samples. The ascorbate free radical concentration was standardized by using 4-hydroxy-2,2,6,6-tetramethyl-piperidine-1-oxyl. After double integration, 10 000 a.u. of the signal height corresponded to 0.144 mmol/l ascorbate free radical. Due to the construction of the flat cell and a special holder as well as fixed instrumental conditions, the precision of the method varied in a small range relative to the boundary of the interindividual differences (Wenzel et al, 1976) . The instrumental settings were modulation amplitude: 1 G, receiver gain: 4 Â 10 5 , conversion time: 82 ms, time constant: 20.5 ms, number of scans: 8.
Measurement of thiobarbituric acid-reactive substances (TBARS)
Measurement of TBARS in human blood plasma was carried out as recently described (Jentzsch et al, 1996) . Briefly, tubes containing 200 ml plasma samples and 10 ml 0.2 mol/l BHT were vortexed, immediately frozen and stored at À701C until further analysis. After thawing 25 ml 0.11 mol/l 2-thiobarbituric acid, the reagent was added, vortexed, incubated at 901C (45 min) and then cooled to 41C. TBARS were extracted with 500 ml butanol and 50 ml saturated NaCl solution was added. The tubes were microcentrifuged in an Eppendorf centrifuge (11 600 Â g, 221C, 60 s) and 250 ml of the upper butanol phase was measured by UV in a 96-well multititer plate. TBARS concentrations were calculated using the difference in absorption at two wavelengths (535 and 572 nmol/l, UNICAM UV 2 spectrophotometer, UK). Of note: TBARS analysis was not influenced by vitamin C in concentrations as high as 2000 mM.
Measurement of 8-oxoguanosine 8-oxoguanosine was analyzed as described before, with minor modifications ( Loft et al, 1992) . In brief, urine was neutralized with 2 N NaOH and 8-hydroxy-2-deoxyguanosine was added. Subsequently, this solution was subjected to HPLC. The first HPLC was performed at neutral pH (7.4, C 18 column) and the second at acidic pH (2.2, Supelcosil LC 18 S 5 mmol/l 250 Â 4.6 mm; flow 1 ml/min). This was followed by electrochemical detection at 140, 210, 280 and 350 mV.
Statistical analysis
Statistical analysis was performed by D Schremmer, GKM Gesellschaft für Therapieforschung mbH, Munich, Germany. For statistical analysis, SAS version 8.02 (SAS Institute, Cary, NC, USA) was used.
An additive model including treatment and period as fixed effects was applied for the plasma concentrations of vitamin C and AFR. A potential biasing effect, which may have arisen due to the crossover study design, could be excluded by showing that both the period effect and the treatmentperiod interaction were not statistically significant (Jones and Kenward, 1989) . Owing to the small sample number, in connection with strongly skewed distributions and considerable differences in standard deviations, nonparametric
No damage by high-dose vitamin Cmethods (ie Wilcoxon test for paired data, respectively, Wilcoxon Mann-Whitney test) were chosen for all statistical analyses. All tests were carried out two-tailed with alpha ¼ 0.05. Due to the pilot character of the study, no confirmative analysis was performed.
Results
Dose-and time-dependent Vitamin C plasma concentrations All volunteers tolerated high-dose intravenous infusions of vitamin C very well. In particular, we noted only one episode of mild thrombophlebitis. Symptoms were self-limiting after 3 days, requiring local cooling only. A temporary increased osmotic load might explain increased thirst, experienced transiently by some probands. No abnormalities in ECGs were observed.
Basal vitamin C plasma concentrations of the volunteers ranged from 30.6 to 113.3 mmol/l with a mean of 61724 mmol/l in the 7500 mg and 65.2727 mmol/l in the 750 mg group, respectively (not significant, n.s.). Upon intravenous application, vitamin C mean plasma concentrations rose sharply after 15 min post infusion (p.i.) in a dosedependent manner. The peak at 15 min was approximately seven-fold higher (2143 vs 311 mmol/l) in the 7500 mg-as compared to 750 mg group (Figures 1, 2) . These supraphysiological vitamin C concentrations can be achieved by intravenous infusions only, as the absorptive capacity in case of a per os administration is limited.
The difference between the two groups diminished gradually, as plasma concentrations declined in a timedependent manner. At 8 h p.i. plasma concentrations were 209759 mmol/l (7500 mg) and 91730 mmol/l (750 mg), at 24 h 91713 and 82719 mmol/l, respectively.
These kinetic curves suggested a first-order elimination, as observed by other groups before (Levine et al, 1996; Graumlich et al, 1997) . The kinetics of vitamin C metabolism are highly complex and described in detail by Graumlich et al (1997) (Washko et al, 1989; Bergsten et al, 1990; Welch et al, 1993; Bergsten et al, 1995; Levine et al, 1996) . For a rough estimate, we used a simplistic model, in which elimination from the plasma (central compartment) occurs solely by renal excretion, following a first-degree order. For this purpose, we used the equation
(1/h) (25)). As depicted in Figures 1 and 2 , elimination followed initially a first-degree order. After 2 h, a relevant discrepancy between estimated and observed values was noted. Of interest, this phenomenon occurred in parallel at supraphysiological plasma concentrations, for example at 806 (7500 mg) and 160 mmol/l (750 mg) vitamin C.
Higher fasting plasma concentrations of vitamin C upon repetitive intravenous vitamin C infusions
Volunteers received daily infusions of 750 or 7500 mg for another 5 days. Fasting vitamin C concentrations increased in both groups, reaching a maximum at 4 days ( Figure 3) . However, when comparing these concentrations with baseline, no significance could be calculated (750 mg, P ¼ 0.156; 7500 mg, P ¼ 0.06). No significant difference with regard to 
No damage by high-dose vitamin C
A Mühlhöfer et al maximal fasting concentration was observed between the two groups (90 vs 100 mmol/l; 750, 7500 mg; P ¼ 0.16) on day 4 either. Covariance analyses were not carried out due to the low number of cases within the crossover design. Therefore, we cannot conclude whether the two treatments resulted in significantly different curves over the whole treatment time.
When comparing vitamin C concentrations at 4 and 8 h p.i., we observed a tendency of higher concentrations on days 2-6 in each group when compared to day 1 (at 4 and 8 h). Moreover, concentrations in the 7500 mg group were somewhat higher at 4 and 8 h each as compared to the 750 mg group. However, statistical analysis did not reveal any significant differences (data not shown).
As we did not observe accumulation of vitamin C in plasma, efficient mechanisms of elimination must be present. Apart from renal excretion in its native state, vitamin C can be removed from the body after metabolization to oxaluric acid. At baseline, mean oxalate concentrations in urine were 37.779.2 and 27.379.2 mg /24 h (7500, 750 mg). On day 6, oxalate increased to 52.3711.7 mg / 24 h and (P ¼ 0.06) and 35.275.2 mg/24 h (P ¼ 0.13; 7500, 750 mg, baseline vs day 6). However, oxalate concentrations of the 7500 and 750 mg group on day 6 differed significantly (Po0.03). This increase of oxalate in urine reflects elevated and daily peaking vitamin C concentrations over the whole study period, rather than increased fasting vitamin C plasma concentrations.
Dose-and time-dependent AFR plasma concentrations
Baseline AFR plasma concentrations ranged from 23.7 to 51.9 nmol/l with a mean of 42.6711.4 nmol/l in the 7500 mg and 3376 nmol/l in the 750 mg group (n.s.). Upon intravenous vitamin C application, AFR concentrations also rose in a dose-dependent manner (Figure 4 ). Mean peak concentrations were 197.1792.4 and 72.3729.7 nmol/l (7500 mg/750 mg). AFR concentration peaks were observed at 15 min in the 750 mg group and at 30 min in the 7500 mg group. We assume that, as compared to vitamin C kinetics, this lag in the 7500 mg group is due to preceding timedependent metabolic steps. This lag in AFR increase is also supportive of the argument that AFR is not generated ex vivo. In this context, it is necessary to mention that AFR ex vivo production could reliably be excluded (data not shown).
AFR concentrations subsequently declined, reaching concentrations of 50.7713.5 nmol/l (7500 mg) and 40.5721.9 nmol/l (750 mg) at 8 h.
Transient peak of fasting AFR plasma concentrations upon repetitive vitamin C infusions
Repetitive high-dose vitamin C infusions led to increased AFR fasting concentrations in both groups. Maximum mean concentrations were observed on day 2 in the 750 mg group (61.5736.3 nmol/l) and on day 3 in the 7500 mg group (72.6735.4 nmol/l). However, we could not detect a statistical difference between the maximal and baseline concentrations (750 mg, P ¼ 0.06; 7500 mg, P ¼ 0.188). Thereafter, a decline was observed in both groups ( Figure 5 ). Again, dose dependency was observed, yielding higher concentrations in the 7500 mg group as compared to the 750 mg group, but without statistical significant difference. A similar pattern was observed at 4 and 8 h (not shown). The reason for this decline is not clear.
Unchanged a-tocopherol, but decreased TBARS plasma concentrations upon vitamin C infusions As high-dose vitamin C infusions might induce lipid peroxidation, we determined plasma concentrations of Figure 3 Repetitive high-dose vitamin C infusions result in a trend towards higher fasting vitamin C plasma concentrations. Volunteers (n ¼ 6) received vitamin C (750 mg/7500 mg) for six consecutive days. Mean plasma concentrations were determined from fasting subjects prior to infusion at baseline (b) and days 2-6. Mean concentrations 7 s.d. are depicted. Figure 4 Plasma AFR concentrations kinetics have a retarded peak. AFR plasma concentrations were determined at baseline (b) and p.i. at time points indicated (n ¼ 6). Statistical differences between the two dosages were observed at 60 and 240 min (Po0.05, Wilcoxon test).
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Tocopherol fasting concentrations ranged from 22.3 to 35.4 mmol/l with a mean of 27.878.5 mmol/l in the 7500 mg and 25.774.3 mmol/l in the 750 mg group at baseline. The mean concentrations remained virtually unchanged during the entire study period (day 6: 24.474.7 and 25.177.3 mmol/ l; 7500 vs 750 mg; n.s.). As no depletion of tocopherol was observed, relevant induction of lipid peroxidation seems to be unlikely.
Basal TBARS plasma concentrations varied considerably between the probands (Figure 6 ). When plotting TBARS against AFR on day 0, we observed a positive correlation (r ¼ 0.56) (not shown). This suggests that each person has an individual set point in regard of oxidative stress, as judged by lipid peroxidation activity. Upon vitamin C infusion, TBARS concentrations declined rapidly in both groups. The mean decline 2 h p.i. was 150 (7500 mg) and 70 nmol/l (750 mg) (not shown). On day 6, AFR concentrations increased slightly, whereas TBARS concentrations were lower in all patients except for one when compared to baseline (Figure 6 ). Of note, TBARS concentrations did not decline below an obviously shared threshold of approximately 320 nmol/l.
Unaltered 8-oxoguanosine urine concentrations upon vitamin C infusions
Baseline values of 8-oxoguanosine concentrations in urine varied considerably between the individuals. When comparing medians of baseline and day 6, a decline (31.7 vs 24.3 nmol/24 h) was registered in the 750 mg group (not shown). In contrast, in the 7500 mg group, amounts of daily excreted 8-oxoguanosine remained unchanged (32.9 vs 32.4 nmol/24 h).
Discussion
This study was performed to characterize the kinetics of vitamin C and AFR upon repetitive high-dose vitamin C infusions. We could demonstrate that fasting plasma concentrations of vitamin C and AFR showed a tendency to increase over the study period. As a rather steady-state-like pattern and no continuous rise of AFR was observed, efficient mechanisms for the elimination of AFR must be present.
In detail, AFR kinetics showed a clear time-and dosedependency upon high-dose intravenous vitamin C (Figure 4 ). Apart from a delayed peak in the 7500 mg group, which can be explained by the lag time necessary for generating AFR, disappearance kinetics correlated closely with vitamin C plasma concentrations. This suggests that plasma vitamin C is the driving force for the production of AFR. Elimination of AFR appeared to be highly efficient, as in both groups AFR returned almost to baseline concentrations after 8 h. The mechanisms that could account for this phenomenon are transmembranous AFR reductases, which were described in erythrocytes and liver (Goldenberg et al, 1983; Villalba et al, 1993; May et al, 2000 May et al, , 2001 . Alternatively, AFR can be oxidized to form DHAA. Moreover, two molecules of AFR can disproportionate, thereby forming one AA and one DHAA molecule.
The fact that AFR is readily eliminated suggests tight control by the enzymes mentioned above. For this reason, induction of pro-oxidative processes seems unlikely. For example, if lipid peroxidation were induced, this selfsustaining process would remove electrons stochiometrically, thereby increasing AFR and TBARS, but decreasing tocopherol plasma concentrations.
During repetitive vitamin C infusions, fasting AFR concentrations increased initially and then dropped to Figure 5 Repetitive intravenous vitamin C application increased, however not significantly, AFR fasting plasma concentrations. Prior to daily vitamin C infusion (750 mg/7500 mg) for 6 days, mean AFR concentrations were measured at baseline (b) and on days 2-6 (n ¼ 6). No statistical differences were noted either between the groups or between baseline and the time points given (Wilcoxon test). Figure 6 Prolonged intravenous vitamin C application led to a decrease of TBARS, but not below a threshold of approximately 320 nmol/l. TBARS were determined prior to infusion and day 6. After 6 days of daily vitamin C infusions (750 mg/day (~) / 7500 mg/day (')), TBARS plasma concentrations were lower in all except for one volunteer, but never below a threshold of approximately 320 nmol/l. No difference was noted between the treatment groups (n ¼ 6; Wilcoxon test).
No damage by high-dose vitamin Cconcentrations slightly above baseline ( Figure 5 ). This fact underlines the efficiency of control of AFR. We speculate that the mechanisms that efficiently eliminate AFR are upregulated. In particular, the NADH-dependent AFR reductase in the erythrocyte membrane or the extracellular AFR reduction by a erythrocyte membrane redox system appear to be likely candidates for this mechanism (Van Duijn et al, 2000; May et al, 2001) .
TBARS were rapidly reduced within 2 h p.i. As this effect persisted in all subjects after 5 days, high-dose vitamin C infusions appear to be a powerful anti-oxidative treatment ( Figure 6 ). However, even with a daily dose of 7500 mg, it was not possible to lower TBARS concentrations below a threshold of approximately 320 nmol/l. Other mechanisms that account for the production of malondialdehydes and that cannot be neutralized by vitamin C action must therefore be present. The possible candidates are lipid peroxides, produced by lipooxygenases or cyclooxygenases. It is important to mention that increasing AFR concentrations are not associated with a concomitant increase of TBARS or decrease of tocopherol concentrations. Therefore, initiation of lipid peroxidation, as proposed by some authors, appears unlikely in vivo (Lee et al, 2001) . A recent vitamin C depletionrepletion study in healthy young women measured plasma and urine concentrations of F 2 -isoprostane, an established marker for lipid peroxidation (Levine et al, 2001) . Upon repletion, F 2 -isoprostane concentrations did not change significantly during the study period (maximal dose: 2500 mg vitamin C p.o. per day).
As induction of self-sustaining lipid peroxidation seems to be unlikely, we cannot exclude the production of genotoxic metabolites. So far, only in vitro experiments demonstrated that vitamin C enhances DNA damaging induced by radiation or peroxynitrite (Cai et al, 2001; Guidarelli et al, 2001) . The relevance of vitamin C-induced genotoxic lipid hydroperoxides, as described by Lee in a cell-free system, has yet to be elucidated (Lee et al, 2001 ). However, it should be taken into consideration that these identified bifunctional genotoxic electrophiles rapidly react with plasma proteins and lipids (IA Blair, Philadelphia, PA; personal communication).
We studied healthy subjects without vitamin C deficiency. We are not certain whether we can extrapolate our results for critically ill patients, who are bound to have an overproduction of ROS. In a study by Galley, septic patients who had lower vitamin C plasma concentrations than healthy controls received 1 g vitamin C intravenously (Galley et al, 1996) . Plasma AFR concentrations, measured 10 min p.i., did not increase as compared to controls. The reason for this might be a measuring AFR too early. Alternatively, this might be due to depletion of vitamin C, but possibly also of other plasma antioxidants, for example, tocopherol. Therefore, as only vitamin C -depleted critically ill patients have been studied so far, it is necessary to assess critically ill patients who were replenished with vitamin C in terms of pro-oxidative damages.
In analogy of the TBARS and tocopherol results, we did not observe any pro-oxidative effects when analyzing 8-oxoguanosine in the urine either. Although the results varied considerably between individuals, the median decreased in the 750 mg group, which is compatible with the findings of other groups (Podmore et al, 1998) . In contrast, the median in the 7500 mg group remained unchanged, indicating that precaution with longer application of high-dose vitamin C might be warranted.
Taken together, high-dose vitamin C therapy is a powerful anti-oxidative and safe therapy. As AFR was rapidly eliminated, concentrations of tocopherol remained stable and TBARS concentrations decreased, there was no evidence of pro-oxidative effects induced by high-dose intravenous vitamin C therapy.
However, there are certain limitations of our study. First, the study and observational period were only 6 days; we therefore cannot predict long-term clinical outcomes. Second, although we had no indication of self-sustaining lipid peroxidation, we cannot exclude the production of genotoxins, which can be hazardous in even very small amounts. As only healthy subjects were studied, we cannot foresee effects in critical ill patients, particularly in these who have a relevant increased production of ROS. Further studies should address this issue.
